Yuri Quintana

Yuri Quintana

Auto-generated profile, based on publicly available information

Yuri Quintana

Beth Israel Deaconess Medical Center, Boston, MA

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 September 2024 in Journal of the American Medical Informatics Association
Verified
Journal Article
Open access
PDF file
SLSteven Labkoff
Steven Labkoff
BOBilikis Oladimeji
Bilikis Oladimeji
JKJoseph Kannry
Joseph Kannry
ASAnthony Solomonides
Anthony Solomonides
RLRussell Leftwich
Russell Leftwich
YQYuri Quintana
Yuri Quintana
Background: Integrating artificial intelligence (AI) in healthcare settings has the potential to benefit clinical decision-making. Addressing challenges such as ensuring trustworthiness, mitigating bias, and maintaining safety is paramount. The lack of established methodologies for pre- and post-deployment evaluation of AI tools regarding crucial attributes such as transparency, performance monitoring, and adverse event reporting makes this situation challenging. Objectives: This paper aims to make practical suggestions for creating methods, rules, and guidelines to ensure that the development, testing, supervision, and use of AI in clinical decision support (CDS) systems are done well and safely for patients. Materials and Methods: In May 2023, the Division of Clinical Informatics at Beth Israel Deaconess Medical Center and the American Medical Informatics Association co-sponsored a working group on AI in healthcare. In August 2023, there were 4 webinars on AI topics and a 2-day workshop in September 2023 for consensus-building. The event included over 200 industry stakeholders, including clinicians, software developers, academics, ethicists, attorneys, government policy experts, scientists, and patients. The goal was to identify challenges associated with the trusted use of AI-enabled CDS in medical practice. Key issues were identified, and solutions were proposed through qualitative analysis and a 4-month iterative consensus process. Results: Our work culminated in several key recommendations: (1) building safe and trustworthy systems; (2) developing validation, verification, and certification processes for AI-CDS systems; (3) providing a means of safety monitoring and reporting at the national level; and (4) ensuring that appropriate documentation and end-user training are provided. Discussion: AI-enabled Clinical Decision Support (AI-CDS) systems promise to revolutionize healthcare decision-making, necessitating a comprehensive framework for their development, implementation, and regulation that emphasizes trustworthiness, transparency, and safety. This framework encompasses various aspects including model training, explainability, validation, certification, monitoring, and continuous evaluation, while also addressing challenges such as data privacy, fairness, and the need for regulatory oversight to ensure responsible integration of AI into clinical workflow. Conclusions: Achieving responsible AI-CDS systems requires a collective effort from many healthcare stakeholders. This involves implementing robust safety, monitoring, and transparency measures while fostering innovation. Future steps include testing and piloting proposed trust mechanisms, such as safety reporting protocols, and establishing best practice guidelines.

10 December 2007 in Cancer
Verified
Journal Article
Closed access
PDF file
SHScott C. Howard
Scott C. Howard
MMMonika L. Metzger
Monika L. Metzger
JWJudith A. Wilimas
Judith A. Wilimas
YQYuri Quintana
Yuri Quintana
CPChing‐Hon Pui
Ching‐Hon Pui
RRRaul C. Ribeiro
Raul C. Ribeiro

27 February 2023 in JMIR Human Factors
Verified
Journal Article
Open access
AJAmanda L. Joseph
Amanda L. Joseph
HMHelen Monkman
Helen Monkman
Andre KushnirukAndre Kushniruk
Andre Kushniruk
YQYuri Quintana
Yuri Quintana
Background: Journey maps are visualization tools that can facilitate the diagrammatical representation of stakeholder groups by interest or function for comparative visual analysis. Therefore, journey maps can illustrate intersections and relationships between organizations and consumers using products or services. We propose that some synergies may exist between journey maps and the concept of a learning health system (LHS). The overarching goal of an LHS is to use health care data to inform clinical practice and improve service delivery processes and patient outcomes. Objective: The purpose of this review was to assess the literature and establish a relationship between journey mapping techniques and LHSs. Specifically, in this study, we explored the current state of the literature to answer the following research questions: (1) Is there a relationship between journey mapping techniques and an LHS in the literature? (2) Is there a way to integrate the data from journey mapping activities into an LHS? (3) How can the data gleaned from journey map activities be used to inform an LHS? Methods: A scoping review was conducted by querying the following electronic databases: Cochrane Database of Systematic Reviews (Ovid), IEEE Xplore, PubMed, Web of Science, Academic Search Complete (EBSCOhost), APA PsycInfo (EBSCOhost), CINAHL (EBSCOhost), and MEDLINE (EBSCOhost). Two researchers applied the inclusion criteria and assessed all articles by title and abstract in the first screen, using Covidence. Following this, a full-text review of included articles was done, with relevant data extracted, tabulated, and assessed thematically. Results: The initial search yielded 694 studies. Of those, 179 duplicates were removed. Following this, 515 articles were assessed during the first screening phase, and 412 were excluded, as they did not meet the inclusion criteria. Next, 103 articles were read in full, and 95 were excluded, resulting in a final sample of 8 articles that satisfied the inclusion criteria. The article sample can be subsumed into 2 overarching themes: (1) the need to evolve service delivery models in health care, and (2) the potential value of using patient journey data in an LHS. Conclusions: This scoping review demonstrated the gap in knowledge regarding integrating the data from journey mapping activities into an LHS. Our findings highlighted the importance of using the data from patient experiences to enrich an LHS and provide holistic care. To satisfy this gap, the authors intend to continue this investigation to establish the relationship between journey mapping and the concept of LHSs. This scoping review will serve as phase 1 of an investigative series. Phase 2 will entail the creation of a holistic framework to guide and streamline data integration from journey mapping activities into an LHS. Lastly, phase 3 will provide a proof of concept to demonstrate how patient journey mapping activities could be integrated into an LHS.

1 August 2010 in European Journal of Cancer
Verified
Journal Article
Closed access
EDEduardo Delgado
Eduardo Delgado
RBRaymond C. Barfield
Raymond C. Barfield
JBJustin N. Baker
Justin N. Baker
PHPamela S. Hinds
Pamela S. Hinds
JYJie Yang
Jie Yang
JKJavier R. Kane
Javier R. Kane

19 June 2025 in International Journal of Medical Informatics
Verified
Journal Article
Open access
LRLeon Rozenblit
Leon Rozenblit
APAmy Price
Amy Price
ASAnthony Solomonides
Anthony Solomonides
AJAmanda L. Joseph
Amanda L. Joseph
EKEileen Koski
Eileen Koski
YQYuri Quintana
Yuri Quintana
The rapid integration of artificial intelligence (AI) into healthcare presents significant governance challenges, requiring balanced approaches that safeguard safety, efficacy, equity, and trust (SEET). This study proposes a cognitive framework to guide AI governance, addressing tradeoffs between speed, scope, and capability. To develop a structured governance model that harmonizes stakeholder perspectives, focusing on multi-dimensional challenges and ethical principles essential for AI in healthcare. A multidisciplinary team convened at the Blueprints for Trust conference, organized by the American Medical Informatics Association (AMIA), and the Division of Clinical Informatics at Beth Israel Deaconess Medical Center. Following extensive discussions with 190 participants across sectors, three governance models were identified to address specific domains: (1) Clinical Decision Support (CDS), (2) Real-World Evidence (RWE), (3) Consumer Health (CH). Three governance models emerged, tailored to CDS, RWE, and CH domains. Key recommendations include establishing a Health AI Consumer Consortium for patient-centered oversight, initiating voluntary accreditation and certification frameworks, and piloting risk-level-based standards. These models balance rapid adaptation with SEET-focused safeguards through transparency, inclusivity, and ongoing learning. A proactive, constraint-based governance framework is critical for responsible AI integration in healthcare. This structured, multi-stakeholder approach provides a roadmap for ethical, transparent governance that can evolve with technological advancements, enhancing trust and safety in healthcare AI applications.

11 May 2020 in Cancer Research
Verified
Journal Article
Open access
PDF file
MHMaxine Harlemon
Maxine Harlemon
OAOlabode Ajayi
Olabode Ajayi
PKPaidamoyo Kachambwa
Paidamoyo Kachambwa
MKMichelle S. Kim
Michelle S. Kim
CSCorinne N. Simonti
Corinne N. Simonti
JLJoseph Lachance
Joseph Lachance
Although prostate cancer is the leading cause of cancer mortality for African men, the vast majority of known disease associations have been detected in European study cohorts. Furthermore, most genome-wide association studies have used genotyping arrays that are hindered by SNP ascertainment bias. To overcome these disparities in genomic medicine, the Men of African Descent and Carcinoma of the Prostate (MADCaP) Network has developed a genotyping array that is optimized for African populations. The MADCaP Array contains more than 1.5 million markers and an imputation backbone that successfully tags over 94% of common genetic variants in African populations. This array also has a high density of markers in genomic regions associated with cancer susceptibility, including 8q24. We assessed the effectiveness of the MADCaP Array by genotyping 399 prostate cancer cases and 403 controls from seven urban study sites in sub-Saharan Africa. Samples from Ghana and Nigeria clustered together, whereas samples from Senegal and South Africa yielded distinct ancestry clusters. Using the MADCaP array, we identified cancer-associated loci that have large allele frequency differences across African populations. Polygenic risk scores for prostate cancer were higher in Nigeria than in Senegal. In summary, individual and population-level differences in prostate cancer risk were revealed using a novel genotyping array.Significance: This study presents an Africa-specific genotyping array, which enables investigators to identify novel disease associations and to fine-map genetic loci that are associated with prostate and other cancers.